Dr. Siegel on Pomalidomide in Lenalidomide-Refractory Patients With Myeloma   

Dr. Siegel on Pomalidomide in Lenalidomide-Refractory Patients With Myeloma

David M. Siegel, M.D., Ph.D., chief of myeloma, John Theurer Cancer Center, professor of medicine, Hackensack Meridian Health, discusses the feasibility of using pomalidomide to treat patients with myeloma who have become refractory to lenalidomide.

READ FULL ARTICLE ON ONCLIV.COM

We use cookies to improve your experience. Please read our Privacy Policy or click Accept.
X